WEBINAR

Assay-ready GPCRs in 48 h: Unveiling eProtein Discovery™ Nanodiscs

nuclera-webinar-gpcrnanodiscannouncment-2048x776px

Sign up:

Summary

Are you waiting weeks for your GPCRs to express, only to watch them aggregate or lose activity during harsh detergent "scouting"? Despite being some of the most valuable drug targets in the industry, GPCRs make up less than 1% of solved structures in the PDB due to these severe production bottlenecks. The problem isn't your downstream structural biology tech—it's getting stable, active protein in the first place.

It is time to skip the cell and the detergent.

Join Dr. Tobias Ost, SVP of Product Development at Nuclera, as we unveil our new, expertly curated eProtein Discovery™ GPCR Nanodiscs. Discover how combining cell-free protein synthesis with co-translational insertion directly into pre-assembled nanodiscs stabilizes GPCRs as they are synthesized. Dr. Ost will demonstrate how the eProtein Discovery™ system automates multiplex screening of GPCR constructs against this new nanodisc panel to identify the optimum membrane scaffold protein and lipid composition, delivering fully functional, assay-ready membrane proteins in just 48 hours.

In this webinar, you’ll learn how to:

  • Skip the Cell and the Detergent: Avoid the destabilizing "extract-then-rescue" sequence by stabilizing GPCRs in a more native-like lipid environment from the very first minute of synthesis.
  • Automate Nanodisc Screening: Leverage digital microfluidics to simultaneously screen your GPCR constructs against our new panel of 8 pre-assembled, GPCR-specific nanodiscs overnight to find the perfect lipid and scaffold match.
  • Maximize Functional Yield: See how co-translational insertion into the optimal nanodisc composition yields functional receptors where traditional detergent extraction or alternative nanodisc compositions fail.
  • Accelerate Structural Workflows: Review a comprehensive case study on the β1 Adrenergic Receptor (β1AR) demonstrating how the platform scaled up the winning nanodisc condition to deliver >100 µg/mL of purified protein with an enriched ~45% active binding fraction in under 72 hours.

This webinar is designed for:

  • Structural Biologists & Cryo-EM Scientists who need stable, well-folded, and active GPCRs without the aggregation and instability caused by harsh detergent extraction.
  • Discovery & Hit-to-Lead Teams in pharma/biotech who are bottlenecked by the slow pace of traditional cell-based expression and need to secure active receptors in days, not weeks.
  • Protein Sciences & Expression Groups looking for automated, cell-free alternatives to rapidly screen construct and lipid environments simultaneously.
  • Biophysicists & Protein Chemists seeking physiologically relevant nanodisc environments to preserve ligand-binding functionality for accurate downstream assays.

Register now to break your GPCR bottleneck and secure decision-grade protein in days, not months.

Speaker:

SVP of Product Development
Toby has 22 years of experience in product development for disruptive NGS and Epigenetics-tools companies such as Solexa, Illumina and PacBio. At Nuclera he leads the Product Development Division, developing cutting-edge protein expression, optimization, detection and binding workflows and integrating them into the eProtein Discovery system. Toby is the tallest member of the Nuclera team and has a love of Marmite and all things Scottish.

About eProtein Discovery

Nuclera's eProtein Discovery™ system combines digital microfluidic droplet automation with cell-free protein synthesis technologies, it empowers protein scientists to identify the best conditions for expressing and purifying proteins of interest within 24 hours, all on a single consumable cartridge.

The system offers a significant advantage over traditional protein expression methods, allowing researchers to save time and resources by simplifying and automating the process. Its ability to handle multiple genes and customizable cell-free blends makes it a valuable tool for protein scientists in academia and the biopharma industry.